Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
06 oct. 2023 09h32 HE
|
Merus N.V.
Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: MCLA-129 in previously treated head & neck...
Merus to Participate in Upcoming Investor Conferences
31 août 2023 08h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus N.V. Announces Proposed Public Offering of Common Shares
09 août 2023 16h01 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing...
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
07 août 2023 16h26 HE
|
Merus N.V.
– Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma – Phase 3 trial of petosemtamab monotherapy in...
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
28 juil. 2023 08h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 28, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
05 juil. 2023 16h01 HE
|
Merus N.V.
– Zeno granted BTD for the treatment of NRG1+ non-small cell lung cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage...
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
29 juin 2023 16h30 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
15 juin 2023 07h47 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
31 mai 2023 08h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
17 avr. 2023 10h15 HE
|
Merus N.V.
- 37% overall response rate (ORR) observed in 43 evaluable patients- 6 months median duration of response as of Feb. 1, 2023 data cutoff date- End-of-phase meeting with U.S. Food & Drug...